Article: Persistent Vaccination Effect of GRAZAX After Completion of Treatment.(Clinical report)

Breakthrough: Results from the fourth year in a long-term clinical study

prove the disease modifying effect of GRAZAX(R). For the first time ever, it is documented that the positive clinical effect of the tablet vaccine persists after completion of treatment (see also ALK-Abello A/S).

Today, ALK announces main results from the first follow-up year in a long-term study (GT-08) with GRAZAX(R), the company's tablet-based vaccine against grass pollen allergy. The clinical study documents that the effect of

GRAZAX(R) persists following completion of the recommended three-year treatment regimen. Furthermore, blood samples from patients show a ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!